In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis
about
Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?Towards a new combination therapy for tuberculosis with next generation benzothiazinonesNew anti-tuberculosis drugs and regimens: 2015 updateDevelopment of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.1,4-azaindole, a potential drug candidate for treatment of tuberculosis.Lansoprazole is an antituberculous prodrug targeting cytochrome bc1.Putting Tuberculosis (TB) To Rest: Transformation of the Sleep Aid, Ambien, and "Anagrams" Generated Potent Antituberculosis Agents.Simple fluorescence-based high throughput cell viability assay for filamentous fungi.Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosisPerspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.A Flow Cytometry Method for Rapidly Assessing Mycobacterium tuberculosis Responses to Antibiotics with Different Modes of ActionBenzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosisInhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister CellsSynergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro.Resistance in tuberculosis: what do we know and where can we go?TMC207 becomes bedaquiline, a new anti-TB drug.The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis.Trends in discovery of new drugs for tuberculosis therapy.The anti-tuberculosis agents under development and the challenges ahead.Synthetic investigational new drugs for the treatment of tuberculosis.Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.Synthesis of 2-(2,4-dihydroxyphenyl)thieno-1,3-thiazin-4-ones, their lipophilicity and anticancer activity in vitro.Azoreductases in drug metabolism.The Antituberculosis Drug Ethambutol Selectively Blocks Apical Growth in CMN Group Bacteria.News on therapeutic management of MDR-tuberculosis: a literature review.Design, syntheses, and anti-tuberculosis activities of conjugates of piperazino-1,3-benzothiazin-4-ones (pBTZs) with 2,7-dimethylimidazo [1,2-a]pyridine-3-carboxylic acids and 7-phenylacetyl cephalosporins.Identification of the anti-mycobacterial functional properties of piperidinol derivatives.Complex genetics of drug resistance in Mycobacterium tuberculosis.Bioenergetics of Mycobacterium: An Emerging Landscape for Drug Discovery.Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosisSynthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites
P2860
Q26824413-7E4A1B49-7CC6-42D8-96C7-F87717A279D0Q27681604-C72C2939-CE5F-4836-9B26-1921CF861372Q28596775-E75CC66D-035F-42D3-98A8-24A54027600FQ33902627-052DA452-9B8B-4887-A683-AD6C27BC1F92Q34057555-F0BA91FB-111C-4914-B62C-0B77FD67359AQ34484243-F098154B-EB23-484B-8FD6-2257B085D7F3Q35589896-A642E0DB-9C2F-46C9-964F-9F80D8149519Q35676526-9E0505FE-66BE-4FFF-A636-1326AC508B0DQ35859964-94187704-F66E-4D4C-81D8-CE1A225E07BFQ36094215-DA31F506-368D-4CB7-B6CB-EAD589A919DEQ37023216-E281909A-E027-4B22-A5BA-A2086848940AQ37089655-95BF47FD-63A2-4632-9310-1258EF7E6A9AQ37234023-5B9ACCC5-CA38-481F-8C67-CB2F23F7B034Q37403156-C36CCBE1-F793-473B-A90F-B85A08EA0CC7Q37644488-7825588E-F531-4174-B912-BC7FD6173B93Q37720810-B598DF9E-E84C-4FAA-9C1B-630E9BC3CB1FQ38124261-186DAEBB-FB00-4B0B-8066-088A218B90F7Q38135901-5C2EB122-0976-43FB-97CC-75353E977D32Q38137731-E6AB5710-0BDE-4DA5-A8E3-74EB628DDA23Q38237221-400CC2E2-BBCE-48EF-8768-EF4811ED5A80Q38617197-7C9B8FF9-AC8B-43E8-AD22-A8DDD22B721BQ38635790-2B95B873-C4B6-4AB0-9A99-02CE8F374BD0Q38751736-0F26FE5B-20AD-48C4-B746-58DAAA4BE769Q38849126-FF8E6E8C-EEE5-4433-9747-F99A9B331AC2Q38881359-E38574B4-D313-414C-BE8E-23A9DEB2E4C2Q38917152-FBF80ADC-10E9-4851-8E33-D55A0FC5054BQ38973367-754A6E84-5B7E-499B-B1FC-A05D476F1611Q39398924-658D33D0-9AA0-4EE8-85E3-DA355982BD62Q39955278-B31C5664-803D-4B5E-98A9-992FEFDC0FCBQ40333807-CFB3B1A0-6D4D-449F-B90E-E04075AC75D6Q45926221-5B96D5BB-E810-4525-AA1C-AA7A3FE69D64Q52688603-5E6EC67E-943D-4F27-A087-6FD7A87A2D5DQ57291166-6723DAEB-08A1-4812-B648-9AC063A07C48Q58866930-9BC24564-C54B-4B21-A5E0-7B1DFAE5E271
P2860
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
In vitro combination studies o ...... nst Mycobacterium tuberculosis
@en
type
label
In vitro combination studies o ...... nst Mycobacterium tuberculosis
@en
prefLabel
In vitro combination studies o ...... nst Mycobacterium tuberculosis
@en
P2860
P356
P1476
In vitro combination studies o ...... nst Mycobacterium tuberculosis
@en
P2093
Benoit Lechartier
Stewart T Cole
P2860
P304
P356
10.1128/AAC.01476-12
P407
P577
2012-08-27T00:00:00Z